BAM
ACAD icon

Belpointe Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Belpointe Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$1.88K – 629
2023
Q1 		$1.88K Hold
100
– – ﹤0.01% 3317
2022
Q4 		$1.59K Buy
+100
New +$1.56K ﹤0.01% 3330

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Belpointe Asset Management's ACAD Position: Q2 2023 in Review

Belpointe Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 100 shares — an estimated $1.88K sold.

Belpointe Asset Management first reported a position in ACAD in Q4 2022 and held it in 2 quarters. The position peaked at $1.88K in Q1 2023. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

  • Belpointe Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 100 Acadia Pharmaceuticals shares in Q2 2023, an estimated $1.88K.
  • Belpointe Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Acadia Pharmaceuticals position peaked at $1.88K in Q1 2023.
  • 236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.